Vertex Pharmaceuticals
Prescription Drugs · Rare Disease Therapeutics

Vertex Pharmaceuticals revenue, results and funding

Vertex Pharmaceuticals filed revenue of $12B for 2025.

Data updated Nov 19, 2026 · Back to the company report
$12BRevenue, 2025
$4BNet income, 2025
VRTXNasdaq

Results by year

YearRevenueNet incomeTotal assetsLANG_CR_S_M_TAX_PAIDLANG_CR_S_M_TAX_EXPENSELANG_CR_S_M_BUYBACKSLANG_CR_S_M_CAPEXLANG_CR_S_M_SBCLANG_CR_S_M_RNDLANG_CR_S_M_OPERATING_INCOMELANG_CR_S_M_CASHLANG_CR_S_M_ACQUISITIONS
2025$12B$4B$25.6B$1.6B$690M$2B$437.6M$685.9M$3.9B$4.2B$5.1B–
2024$11B−$535.6M$22.5B$1.1B$784.1M$1.2B$297.7M$698.5M$3.6B−$232.9M$4.6B$0
2023$9.9B$3.6B$22.7B$1.7B$760.2M$427.6M$200.4M$581.2M$3.2B$3.8B$10.4B$0
2022$8.9B$3.3B$18.2B$1.1B$910.4M$0$204.7M$491.3M$2.5B$4.3B$10.5B$295.9M
2021$7.6B$2.3B$13.4B$476.3M$388.3M$1.4B$235M$441.4M$3.1B$2.8B$6.8B$0
2020$6.2B$2.7B$11.8B$191.8M$405.2M$539.1M$259.8M$429.5M$1.8B$2.9B$6B$0
2019$4.2B$1.2B$8.3B$24.7M$218.1M$186M$75.4M$360.5M$1.8B$1.2B$3.1B$1.2B
2018$3B$2.1B$6.3B$12.4M−$1.5B$350M$95.4M$325M$1.4B$635.2M$2.7B$0
2017$2.5B$263.5M$3.6B$6.4M−$107.3M$0$99.4M$293.2M$1.3B$123.2M$1.7B$0
2016$1.7B−$112.1M$2.9B−$2.6M$16.7M$0$56.6M$240.6M$1B$9.9M$1.2B–
2015$1B−$556.3M$2.5B$1.8M$30.4M–$45.3M$231M$995.9M−$466.9M$714.8M–
2014$580.4M−$738.6M$2.3B$1.2M$7M–$51.2M$177.5M$855.5M−$692.4M$625.3M–
2013$1.2B−$445M$2.3B$2.8M−$122.4M–$51.4M$127.3M$882.1M−$610M$569.3M–
2012$1.5B−$107M$2.8B$9.3M−$275k–$71.1M$114.3M$765.9M$46.7M$489.4M–
2011$1.4B$29.6M$2.2B$0$19.3M–$34.6M$118.2M$707.7M$113.8M$475.3M–
Sources: SEC

How to cite

Vertex Pharmaceuticals, Financials. Alion, Nov 19, 2026. https://alion.io/company/vrtx/financials

.json · .md · CC BY-SA 4.0